export default function MelanoranIOverviewPanel() {
  return (
    <div className="reta-overview">

      <p className="reta-overview__opener">
        Melanotan I &mdash; the same molecule as the pharmaceutical drug afamelanotide &mdash; drives melanin production in the skin without requiring UV exposure. Its medical form is FDA-approved for a rare condition called erythropoietic protoporphyria, where it significantly extends how much time patients can spend in sunlight without agonizing pain. Community use for cosmetic tanning strips out the dermatology monitoring that the pharmaceutical approval requires. The tanning effect is real; the risk management in unmonitored use is not.
      </p>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 1</div>
        <h3 className="reta-overview__profile-heading">The Tanning and Sun Protection Curious Person &mdash; Cosmetic Tan Without Sun Damage</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I burn easily and hate how I look pale, but I also don&rsquo;t want to risk skin cancer from tanning beds. Is Melanotan I actually a safer way to get a tan?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>It drives melanin production without requiring UV radiation</strong><br />Your skin darkens when UV light damages DNA, triggering a stress signal that activates melanocytes to produce melanin as protection. Melanotan I bypasses the UV damage step entirely &mdash; it goes directly to the receptor on melanocytes that tells them to produce melanin now. The darkening is real and can be substantial. For someone who wants color without the UV exposure that causes skin aging and cancer risk, the mechanism has genuine appeal.</li>
          <li><strong>It&rsquo;s more selective than Melanotan II &mdash; fewer of the side effects that made MT-II notorious</strong><br />Melanotan II (a different compound) hit multiple receptors and caused erections, appetite suppression, nausea, and other off-target effects. Melanotan I primarily targets the receptor responsible for pigmentation, which is why afamelanotide became the pharmaceutical form &mdash; more selective, more predictable profile for the intended purpose.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The FDA-approved version of this molecule requires a Risk Evaluation and Mitigation Strategy &mdash; patients must be enrolled in a program with dermatologist monitoring because activating melanocytes without dermatology screening for moles and skin lesions carries real risk. People with many moles, dysplastic nevi, or a family history of melanoma are the specific concern. Melanocyte activation in pre-existing atypical moles could be a problem. Community tanning use removes all of that risk management. Net: the tanning effect is real; the cosmetic tanning use case strips out the safety framework the pharmaceutical approval was built on.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 2</div>
        <h3 className="reta-overview__profile-heading">The Outdoors Athlete &mdash; Sun Protection and Extended Sun Exposure</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I spend a lot of time outside training and competing. Would Melanotan I actually provide meaningful photoprotection, or is this just about appearance?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>Melanin is a real physical UV filter, not just cosmetic</strong><br />The melanin that Melanotan I induces is the same melanin that provides natural photoprotection. Darker skin has a higher melanin density that absorbs UV radiation before it can damage DNA in deeper skin layers. The photoprotection from induced melanin is real, though limited &mdash; it roughly corresponds to an SPF of 2&ndash;4 in light-skinned individuals. For an athlete spending hours outdoors daily, even marginal additional photoprotection stacks with sunscreen.</li>
          <li><strong>For the specific EPP population, the documented benefit is substantial</strong><br />Erythropoietic protoporphyria causes severe, burning pain from even brief sun exposure. In the afamelanotide clinical trials, patients were able to spend significantly more time outdoors without triggering pain episodes &mdash; hours more per day. The photoprotection in a photosensitive population is clinically meaningful. This is the use case where the evidence is strongest.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">For a healthy athlete without EPP, the photoprotection benefit is modest &mdash; SPF 2&ndash;4 is not meaningful sun protection on its own. Sunscreen with SPF 30+ and protective clothing remain the primary sun protection tools, and Melanotan I does not replace them. The regulatory framework for afamelanotide in EPP includes dermatology oversight because of the melanocyte activation concern &mdash; an athlete self-administering for photoprotection is outside that framework. Net: the photoprotection is real but modest for a healthy person; the risk monitoring framework that pharmaceutical use requires is absent in self-administration contexts.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 3</div>
        <h3 className="reta-overview__profile-heading">The Skin Biology Researcher &mdash; Melanocortin System and MC1R Pharmacology</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I want to understand the MC1R selectivity profile of afamelanotide versus alpha-MSH versus Melanotan II, and what the REMS program for EPP actually requires dermatologists to monitor.&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why it&rsquo;s worth understanding</p>
        <ol className="reta-overview__profile-why">
          <li><strong>MC1R selectivity is what separates Melanotan I from the rest of the melanocortin family</strong><br />Alpha-MSH activates MC1R through MC5R. Melanotan II is a non-selective analog that hits MC1R, MC3R, MC4R, and MC5R &mdash; the MC4R agonism drives the sexual arousal and appetite effects that made it notorious. Afamelanotide/Melanotan I was engineered for MC1R selectivity, which is the receptor specifically responsible for melanocyte stimulation and pigmentation. The selectivity engineering is the pharmacological basis for the cleaner side effect profile, and it illustrates how melanocortin receptor subtype targeting changes the therapeutic and adverse effect phenotype.</li>
          <li><strong>The REMS program for Scenesse defines what responsible clinical monitoring looks like</strong><br />The FDA-approved afamelanotide REMS requires certified dermatologists who have been trained in the program, baseline and ongoing skin examination for atypical moles and lesions, patient education on sun protection, and reporting of adverse events. This is the safety framework for a drug that activates melanocytes in a monitored population. Understanding the REMS requirements is useful context for evaluating what community use without this framework actually means: it means removing each of these elements.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The research peptide &ldquo;Melanotan I&rdquo; sold through community channels is the same molecular structure as afamelanotide but is not the same pharmaceutical product &mdash; purity, sterility, and dosing precision are not equivalent to the pharmaceutical form used in clinical trials. The dermatology monitoring requirement in the REMS is not bureaucratic overhead &mdash; it reflects a genuine scientific concern about melanocyte activation in people with elevated baseline melanoma risk. MC1R risk alleles (red hair, light skin, many atypical nevi) are the population most likely to seek cosmetic tanning and also the population with the highest melanoma risk. Net: pharmacologically clean MC1R agonist with real clinical applications; the community tanning use case operates without the risk stratification that the pharmaceutical program built in.</p>
      </div>

      <div className="reta-overview__bottom">
        <p className="reta-overview__bottom-heading">The honest bottom line</p>
        <div className="reta-overview__bottom-cols">
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What Melanotan I is NOT</p>
            <ul className="reta-overview__bottom-list">
              <li>Not the same as Melanotan II &mdash; significantly more receptor-selective and does not produce the erections, appetite suppression, or cardiovascular signals of MT-II</li>
              <li>Not a replacement for sunscreen &mdash; the SPF equivalent of induced melanin is modest (roughly 2&ndash;4 for light-skinned individuals)</li>
              <li>Not risk-free for people with many moles, dysplastic nevi, or melanoma history &mdash; dermatology screening is the point of the pharmaceutical REMS program</li>
              <li>Not pharmaceutical-grade when purchased through community channels &mdash; purity and sterility are not equivalent to the Scenesse formulation</li>
              <li>Not a longevity or performance compound &mdash; it is specifically a pigmentation drug with one approved medical indication</li>
            </ul>
          </div>
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What makes it interesting</p>
            <ul className="reta-overview__bottom-list">
              <li>FDA-approved pharmaceutical form (afamelanotide / Scenesse) with real clinical trial data for EPP &mdash; meaningful documented benefit for a genuine medical condition</li>
              <li>A clean example of melanocortin receptor subtype selectivity engineering &mdash; MC1R targeting without the MC4R side effects of Melanotan II</li>
              <li>The EPP use case is compelling: patients who were largely confined indoors can participate in normal outdoor life &mdash; the quality-of-life data is meaningful</li>
              <li>The REMS framework is a useful model of what appropriate risk management for a melanocyte-activating compound looks like in practice</li>
            </ul>
          </div>
        </div>
      </div>

    </div>
  );
}
